优化急性胆管炎患者的短期抗生素治疗:BOLT-P3开放标签随机对照试验研究方案
这项多中心、非盲法随机试验旨在评估急性胆管炎患者经成功胆道引流后1-3天静脉抗生素短程治疗相较于4-7天标准疗程的非劣效性,主要结局为ERCP术后14天内临床治愈率。研究计划纳入210例受试者,采用最小化法分组并按病情严重程度和医疗机构分层,单侧显著性阈值2.5%、非劣效界值10%、统计效能90%。
要点
- 东京指南2018推荐胆道引流后抗生素使用4-7天,但该推荐缺乏强证据,主要基于异质性临床发现和专家意见。
- 近期回顾性研究主张1-3天短程抗生素治疗急性胆管炎有效,促使重新评估疗程以兼顾疗效并减少耐药和不良反应。
- 本3期试验旨在确定短程治疗相较标准疗程的非劣效性,缩短抗生素疗程可能减少耐药菌出现、不良事件、住院时间和医疗费用。
核心结论
- 本3期试验旨在确定短程治疗相较标准疗程的非劣效性。
- 缩短抗生素给药时间可能减少耐药菌出现、不良事件,并缩短住院时间和降低医疗费用。
研究设计与样本
- 多中心、非盲法随机试验,比较短程治疗与标准疗程治疗急性胆管炎的疗效。
- 短程治疗组在成功胆道引流后接受1-3天静脉抗生素治疗,标准疗程组在成功胆道引流后接受4-7天静脉抗生素治疗。
- 采用最小化法进行非盲法随机分组,分层因素包括病情严重程度和医疗机构。
- 计划纳入210例受试者,以达到90%统计效能,单侧显著性阈值2.5%,非劣效界值10%。
- 主要结局为内镜逆行胰胆管造影术(ERCP)术后14天内的临床治愈率。
关键数值与推荐
- 东京指南2018(TG18)推荐胆道引流后抗生素给药4-7天。
- 近期回顾性研究主张1-3天短程抗生素治疗急性胆管炎有效。
局限性
- 东京指南2018推荐胆道引流后抗生素给药4-7天,但该推荐缺乏强证据,主要基于异质性临床发现和专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute cholangitis (AC) frequently presents as a community-acquired infection and is associated with a high prevalence of antibiotic use among infectious diseases. The Tokyo Guidelines 2018 (TG18) recommend 4-7 days of antibiotic administration after biliary drainage. However, this recommendation lacks strong evidence of its effectiveness and is primarily based on heterogeneous clinical findings and expert opinions. Recent retrospective studies have advocated a shorter 1- to 3-day antibiotic course as effective for AC treatment, prompting the need to reassess the treatment duration to achieve therapeutic efficacy while minimizing resistance and adverse effects. METHODS: We designed a multicenter, non-blinded, randomized trial to evaluate the efficacy of short-course therapy compared to standard-course therapy for AC management. The short-course therapy group will receive 1-3 days of intravenous (IV) antibiotic treatment after successful biliary drainage compared to 4-7 days of IV antibiotics after successful biliary drainage for the standard-course therapy group. The primary outcome is the clinical cure rate within 14 days from the endoscopic retrograde cholangiopancreatography (ERCP) procedure. Participants will be allocated to either treatment course using a minimization method in a non-blinded, randomized manner, with stratification factors including condition severity and facility. We determined that 210 participants would be required to achieve a statistical power of 90% with a one-sided significance threshold of 2.5% and a non-inferiority limit of 10%. DISCUSSION: This phase 3 trial aims to determine the non-inferiority of short-course therapy over standard-course therapy. Shortening the duration of antibiotic administration may mitigate the emergence of resistant bacteria, adverse events, and reduce hospital stay length and healthcare costs. https://jrct.niph.go.jp/re/reports/detail/73862 TRIAL REGISTRATION: This study was registered at the Japan Registry of Clinical Trials under registry number jRCT1031230709. Registered on 14 March 2024, https://jrct.niph.go.jp/re/reports/detail/73862.
引用
- Masuda S, Imamura Y, Kimura K, et al. Optimizing short-term antibiotic treatment in patients with acute cholangitis: study protocol for an open-label randomized controlled trial (the BOLT-P3 trial). Trials. 2025. PMID: 40890775. doi:10.1186/s13063-025-09077-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。